厄达替尼对膀胱癌有效。

Cancer Discov. 2018 Aug;8(8):OF6. doi: 10.1158/2159-8290.CD-NB2018-085. Epub 2018 Jun 27.

Findings from a phase II study indicate clinical efficacy with erdafitinib in patients with -altered inoperable or metastatic urothelial carcinoma. Robust responses were seen with this investigational pan-FGFR inhibitor, including in patients who did not respond to prior immunotherapy.

一项II期研究的结果表明，erdafitinib对具有特定改变的不可切除或转移性尿路上皮癌患者具有临床疗效。这种研究性的泛FGFR抑制剂产生了显著的反应，包括对先前免疫治疗无反应的患者。